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Signal transductionRhoGDI (Rho GDP-dissociation inhibitor alpha, or RhoGDIa) was identiﬁed as a regulator of Rho GTP-
ases, but its role in cancer remains controversial. In this study, increased expression of RhoGDI was
detected in hepatocellular carcinoma (HCC) cell lines and tissues with highly metastatic potential.
RhoGDI overexpression correlated with postoperative distant metastasis. Enforced expression of
RhoGDI in HCC cells signiﬁcantly enhanced cell proliferation and migration. Conversely, knockdown
of RhoGDI caused an inhibition of the aggressive phenotypes of HCC cells. Furthermore, RhoGDI up-
regulated Rho, but not Rac, and enhanced PI3K/AKT and MAPK pathway activity. Our ﬁndings sug-
gest that RhoGDI overexpression is a predictor of distant metastasis and plays an important role in
the progression of HCC.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction could mediate several processes during tumorigenesis and cancerHepatocellular carcinoma (HCC) is one of the most common
malignant disorders, becoming the third leading cause of cancer-
related deaths globally [1]. Usually, it is common observed in
certain areas of Asia and Africa, however, in recent years, an
increasing incidence has been found in Western countries [2].
The prognosis of HCC after surgical or locoregional therapies is still
in its poor position, resulting in ongoing researches [3]. With the
increasing understanding of the tumor biology of HCC, more and
more molecular markers with high sensitivity and speciﬁcity for
HCC have been developed for early diagnosis and the development
of future targeted HCC therapeutics.
Rho GDP-dissociation inhibitors (GDIs), the key regulators of
Rho family GTPases, are typiﬁed by its ability to prevent nucleotide
exchange and membrane association. Despite the initial negative
roles attributed to RhoGDI, recent evidence has come to suggest
that it may also act as a positive regulator necessary for the correct
targeting and regulation of Rho activities by conferring cues for
spatial restriction, guidance and availability to effectors [4,5]. The
expression of RhoGDIs is altered in a variety of cancers, whichprogression [6–9].
In our previous study, RhoGDI was identiﬁed as an up-regulated
protein inmetastatic colorectal cancer (CRC)by comparativeproteo-
mic analysis [10]. The further data suggested that RhoGDI may pro-
mote CRC progression by stimulating tumor cell growth and
migration [11]. miR-151 was revealed as a crucial stimulus for HCC
invasion and metastasis by directly targeting RhoGDI with small-
samples assay [12]. Despite its critical cellular function, the clinical
signiﬁcance and role of RhoGDI in HCC progression is unclear.
In the present study, we detected RhoGDI expression in primary
HCC using immunohistochemistry, and analyzed the relationship
between its over-expression and clinicopathological features. Fur-
ther, the potential predictive value of RhoGDI was evaluated in the
post-resectional metastasis and survival of HCC patients. Gene
transfection-mediated over-expression and RNA interference
(RNAi)-mediated gene silencing were performed to investigate
the effect of RhoGDI on the biological behavior of HCC cells and
discussed the possible mechanisms involved in HCC progression.
2. Materials and methods
2.1. Tumor tissue sample
All cases of tumor tissue were provided by the Tumor Tissue
Bank of Nanfang Hospital. A total of 163 patients were involved
in the study. Fresh frozen tumor samples from 16 patients with
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tissues from other 147 patients including 126 tumor tissues and
106 adjacent non-tumors tissues were used for immunohisto-
chemical analysis. The patients diagnosed of primary HCC had
undergone elective surgery for HCC in Nanfang Hospital during
2001–2002. A comprehensive clinicopathological dataset including
age, gender, size of primary tumor, tumor differentiation, serum al-
pha-fetoprotein (AFP), hepatitis B surface antigen (HBsAg), liver
cirrhosis, local recurrence and distant metastasis were obtained
from the Tumor Tissue Bank of Nanfang Hospital. Complete fol-
low-up, ranging from 0 to 83 months, was available for all patients
and the median follow-up was 42 months. At the time of censoring
the data, there had been 89 (60.5%) deaths in the patient group.
The pathological diagnosis was performed at the Department of
Pathology of Nanfang Hospital, Southern Medical University. The
study was approved by the Ethics Committee of Southern Medical
University and all aspects of the study comply with the Declaration
of Helsinki. Ethics Committee of the Southern Medical University
speciﬁcally approved that not informed consent was required be-
cause data were going to be analyzed anonymously. All patient
data were de-identiﬁed for analysis.
2.2. Cell lines
Human liver immortal cell line L02 was obtained from the Com-
mittee of Type Culture Collection of Chinese Academy of Sciences
(Shanghai, China). HCC cell lines Huh-7 (RCB 1366) was obtained
from the RIKEN cell bank (Ibaraki, Japan). Hep3B (HB-8064), HepG2
(HB-8065) and SK-Hep1 (HTB-52) were obtained from American
Type Culture Collection (ATCC). MHCC-97L, MHCC-97H, HCC-LM3
and HCC-LM6, kindly provided by Liver Cancer Institute of
Zhongshan Hospital, Fudan University (Shanghai, China) [13,14].
All the cells were maintained in RPMI1640 (Hyclone, Logan, UT)
or Dulbecco’s modiﬁed Eagle’s medium (Gibco BRL, USA) supple-
mented with 10% fetal bovine serum (FBS) (Gibco BRL, Invitrogen,
Paisley, UK) at a humidity of 5% CO2 at 37 C. All the cell lines were
characterized by mycoplasma detection, DNA – Fingerprinting,Fig. 1. Expression analysis of RhoGDI in HCC cells and tissues by Western blotting. (A) Ex
lines Hep3B, Huh7, SEK-Hep1, HepG2, MHCC-97L, MHCC-97H, HCC-L3 and HCC-L6 byWe
metastasis. nmHCC, non-metastatic HCC. mHCC, metastatic HCC. (B and D) Immunosign
cells (B) and tissues (D) was calculated as RhoGDI expression relative to GAPDH expresisozyme detection and cell vitality detection. These cell lines were
immediately expanded and frozen such that they could be re-
started every 3–4 months from a frozen vial of the same batch of
cells.
2.3. Western blot analysis
Sample preparation for immunoblotting was done as previously
described [10,15,16]. The membrane was probed with anti-RhoGDI
rabbit polyclonal antibody (1:1000; CST, Danvers, MA, USA), rabbit
polyclonal antibodies to p-Akt (Ser473), p-Akt (Thr308), AKT, p44/
42 MAPK (ERK1/2), p-p44/42 MAPK (ERK1/2) (1:1000; CST, Dan-
vers, MA), rabbit monoclonal antibody to Rho, Rac/Cdc42 (1:500;
Epitomics, California, USA). Protein expression was determined
with horseradish peroxidase-conjugated anti-rabbit immunoglob-
ulin G (1:10000; Zhongshan Jinqiao Biotech, China) and enhanced
chemiluminescence (ECL) (Pierce, Rockford, IL, USA). The immuno-
reactive bands were visualized and quantiﬁed on Kodak 2000 M
camera system (Eastman Kodak, Rochester, NY, USA) according to
the instructions of the manufacturer. The band intensity was mea-
sured by densitometry using the Quantity One software (Bio-Rad
Lab, Hercules, CA). The protein levels were normalized with respect
to that of b-actin or GAPDH (1:500; Santa Cruz Biotechnology,
Santa Cruz, CA). All experiments were repeated more than three
times and representative results were shown.
2.4. Immunohistochemistry (IHC)
Immunohistochemistry was performed, as previously described
[15]. The sections were incubated with primary antibodies against
RhoGDI (1:50) for one hour at room temperature. The slides were
reviewed by two or three pathologists blind to the study. To
evaluate RhoGDI expression levels, immunostained slides were
evaluated using a method described previously [15,17]. Scores
representing the percentage of positive cells were as follows: 0%
(absent), 1–5% (sporadic), 6–25% (local), 26–50% (occasional),
51–75% (majority) and 76–100% (large majority). Intensity ofpression of RhoGDI was detected in human liver immortal cell line L02 and HCC cell
stern blotting. (C) Expression of RhoGDI was detected in HCC tissues with or without
als were quantiﬁed by densitometric scanning. RhoGDI expression in the individual
sion. Data are means ± SD from three independent experiments.
Table 1
Correlation between the clinicopathological features and RhoGDI expression.
Characteristics RhoGDI expression
Negative (%) Positive (%) P value
Group
Non-tumor 103 (97.2) 3 (2.8) <0.001*
Tumor 82 (65.1) 44 (34.9)
Gender
Male 76 (67.9) 36 (32.1) 0.064
Female 6 (42.9) 8 (57.1)
Age
<50 51 (72.9) 19 (27.1) 0.041*
P50 31 (55.4) 25 (44.6)
Tumor size (cm in diameter)
65 27 (62.8) 16 (37.2) 0.698
>5 55 (66.3) 28 (33.7)
Tumor differentiation
Low 14 (82.4) 3 (17.6) 0.742
Middle 27 (57.4) 20 (42.6)
High 41 (66.1) 21 (33.9)
Liver cirrhosis
No 38 (67.9) 18 (32.1) 0.559
Yes 44 (62.9) 26 (37.1)
HBsAg status
Negative 7 (43.8) 9 (56.2) 0.055
Positive 75 (68.2) 35 (31.8)
Serum AFP
Negative 20 (58.8) 14 (41.2) 0.371
Positive 62 (67.4) 30 (32.6)
Local recurrence
No 23 (29.5) 55 (70.5) 0.487
Yes 17 (35.4) 31 (64.6)
Distant metastasis
No 74 (71.8) 29 (28.2) 0.001*
Yes 8 (34.8) 15 (65.2)
* Statistically signiﬁcant (P < 0.05).
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staining, light yellow), 2 (moderate staining, yellowish brown),
and 3 (strong staining, brown). An intensity score of P2 with at
least 50% of RhoGDI positive cells was considered as having high
expression (or over-expression), and <50% of RhoGDI positive cells
or <2 in intensity score was regarded as low expression. The
discrepancies (<5%) were resolved by simultaneous re-evaluation.
2.5. Statistical analysis
All statistical analyses were carried out using the SPSS 12.0
statistical software package. Mann–Whitney U test was used to
analyze the relationship between RhoGDI over-expression and
clinicopathologic characteristics. Survival curves were plotted by
the Kaplan–Meier method and compared by the log-rank test.
The signiﬁcance of various variables for survival was analyzed by
the Cox proportional hazards model in the multivariate analysis.
P < 0.05 in all cases was considered statistically signiﬁcant.
3. Results
3.1. RhoGDI expression results analyzed by Western blot
The protein level of RhoGDI in HCC cell lines was detected by
Western blot. As shown in Fig. 1, of the 16 total HCC tumorous
tissues, an increase in LASP-1 expression was seen in HCC tissues
of patients with metastasis compared with that without metastasis
(P = 0.02). Compared with liver immortal cell line L02, LASP-1
expression was signiﬁcantly increased in Hep3B, HepG2,
MHCC-97L, MHCC-97H, HCC-LM3 and HCC-LM6 cells. Interest-
ingly, a gradually increased trend of immunoreactivity was found
in 4 cell lines (MHCC-97L, MHCC-97H, HCC-LM3 and HCC-LM6)
derived from the same patient, along with the increase of
metastatic potentials.
3.2. RhoGDI is over-expressed in HCC tissues
RhoGDI expression was detected in cytoplasm of liver cells. IHC
was performed to localize RhoGDI expression in 58.5% (62 of 106)
of adjacent non-tumorous tissues tested. As compared to these
non-tumorous tissues, we observed RhoGDI protein expression inFig. 2. Expression analysis of RhoGDI in HCC by immunohistochemistry. (A) Negative
RhoGDI in adjacent non-tumorous tissue. (C–F) High expression (or overexpression) of
picture. (G) Graphical illustration of statistical RhoGDI distribution. RhoGDI is signiﬁcantl
RhoGDI (RhoGDI+) and low RhoGDI (RhoGDI) expression in HCC with or without local re
distant metastasis (DM+) than in HCC without distant metastasis (DM). (J) Kaplan–M
overexpression. The log-rank test was used to calculate P values.68.3% (86 of 126) of all HCC samples (P = 0.123). According to
reclassiﬁcation as described above, RhoGDI was evaluated as high
expression in 34.9% (44 of 126) of all HCC samples, compared with
2.8% (3 of 106) of adjacent non-tumorous tissues tested (P < 0.001;
Fig. 2, Table 1).expression of RhoGDI in adjacent non-tumorous tissue. (B) Positive expression of
RhoGDI in HCC tissues. Scale bars were showed in the lower right corner of each
y higher in HCC (T) than adjacent non-tumorous tissue (NT). (H) Distribution of high
currence (LR or LR+). (I) High expression of RhoGDI is more frequently in HCC with
eier survival analysis of overall survival in patients with HCC according to RhoGDI
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clinicopathological features
To evaluate the clinical relevance of RhoGDI over-expression,
RhoGDI protein was compared to clinicopathological and biological
parameters. As shown in Table 1, there was no signiﬁcant correla-
tion between expression of RhoGDI protein and gender, tumor size,
tumor differentiation, hepatitis B surface antigen (HBsAg), liver
cirrhosis except age of HCC patients.
3.4. RhoGDI over-expression is closely related to postsurgical
metastasis of patients with HCC
To investigate the predict value of RhoGDI over-expression, we
performed a long-term follow-up study to understand local recur-
rence, distant relapse and overall survival of patients with HCC.
Importantly, RhoGDI over-expression were associated with a sig-
niﬁcantly higher incidence of distant relapse (P = 0.001; Table 1),
while no signiﬁcant association with local recurrence was found
(P = 0.487; Table 1). Further, no signiﬁcant trend toward poorerFig. 3. RhoGDI promoted aggressive phenotypes of HCC cells. (A) Transfection efﬁcien
protein expression compared to empty vector transfected HepG2 cells (Left panel). Th
RhoGDI protein expression compared to negative control (NC) siRNA transfected Hep
proliferation was detected by CCK-8 assay. (C) Migration potential was measured in trans
(B and C) Left panel, HepG2 cells transfected with RhoGDI cDNA. Middle panel, HepG2 ce
with RhoGDI siRNA 1 and 2. Data represent mean ± SD of three different experiments.survival for patients whose primary tumors showed high
expression of RhoGDI, compared with those patients whose pri-
mary tumors showed low expression of RhoGDI (Log rank = 0.005,
P = 0.942; Fig. 2J).
3.5. RhoGDI promotes the aggressive phenotype of HCC cells in vitro
We performed gene transfection and RNA interference to inves-
tigate the role of RhoGDI in biological behavior of HCC cells in vitro.
Human RhoGDI cDNA was successfully transfected into HepG2
cells to establish a RhoGDI-overexpressing cell line. Inversely, siR-
NA transfection was employed to knock-down RhoGDI expression
in HepG2 and MHCC-97H cells. The transfection efﬁciency was
conﬁrmed by Western blot analysis (Fig. 3A). The two most
effective siRNA was used to down-regulate endogenous RhoGDI
expression. A signiﬁcantly slower proliferation rate was observed
in RhoGDI siRNA-transfected HepG2 and MHCC-97H cells when
compared with control cells (Fig. 3B). Cell migration analysis
demonstrated that depletion of RhoGDI in cancer cells strongly
reduced cell migration (Fig. 3C), suggesting that RhoGDI wascy of HepG2 and MHCC-97H cells. RhoGDI cDNA efﬁciently up-regulated RhoGDI
ree RhoGDI speciﬁc siRNA, especially siRNA 1 and 2, signiﬁcantly down-regulated
G2 (middle panel) and MHCC-97H (right panel). (B) The ability of in vitro cell
well cell culture chamber. Cells were counted under high power ﬁeld of microscopy.
lls transfected with RhoGDI siRNA 1 and 2. Right panel, MHCC-97L cells transfected
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sion increased the proliferative ability of HepG2 cells. Migration
analysis indicated that exogenous expression of RhoGDI in cancer
cells cased a signiﬁcant increase in cell motility.
3.6. RhoGDI regulated Rho expression, activated PI3K/Akt and MAPK
pathways
To better understand the mechanisms that facilitate the aggres-
sive behavior mediated RhoGDI, the expression levels of signal
pathway. As shown in Fig. 4, RhoGDI may regulate expression of
Rho, but not Rac/Cdc42, which are the members of Rho family
small GTPases. RhoGDI overexpression signiﬁcantly promoted the
phosphorylation of p44/42 MAPK (ERK1/2) and AKT at Thr308 in
HepG2 cells. Inversely, RhoGDI knockdown inhibited the phos-
phorylation of p44/42 MAPK (ERK1/2) and AKT at Thr308 in HepG2
and MHCC-97H cells.
4. Discussion
Rho family GTPases are essential in a variety of cellular func-
tions, which were initially linked to changes in the ﬁlamentous ac-
tin system involving the formation of stress ﬁbres, membrane
rufﬂes/lamellipodia and ﬁlopodia respectively [18]. Now, they play
roles in many aspects of cellular regulation including morphology
and migration, gene transcription, cell cycle progression [19]. Rho
GDIs could prevent nucleotide exchange and membrane associa-
tion by extracting Rho family GTPases from membranes and solu-
bilizing them in the cytosol. Moreover, they interact only with
prenylated Rho proteins both in vitro and in vivo [20,21]. One
important member of human Rho GDIs has been identiﬁed as Rho-
GDI (or GDIa/GDI1) [22,23].
Despite their critical cellular function, the role of RhoGDI in var-
ious kinds of cancers remains controversial. It is reported that the
expression levels of RhoGDI have been up- or down-regulated in
certain cancers [10–12,24–27] and in other pathological conditions
[28,29]. A study based on proteomic analysis showed that RhoGDI
was upregulated in oral squamous cell carcinoma [26]. Our previ-
ous study showed that RhoGDI was up-regulated in CRC [11], sug-
gesting its important role in CRC genesis. However, a recentFig. 4. RhoGDI up-regulated Rho expression and activated MAPK and PI3K/AKT path
phosphorylated level of p44/42 MAPK (ERK1/2) and AKT. Left panel, HepG2 cells transfec
and 2. Right panel, MHCC-97L cells transfected with RhoGDI siRNA 1 and 2. The asterisk
experiments.research showed that deregulation of RhoGDI is frequently down-
regulated in HCC [12]. In the study based on cell lines and a larger
number of clinical samples, however, a signiﬁcantly high incidence
rate of RhoGDI overexpression was found in HCC cells and samples
compared with control groups tested.
Recent evidence has come to suggest that it may also act as a
key regulator necessary for the progression of HCC. Our previous
study has identiﬁed RhoGDI as an up-regulated protein in meta-
static colorectal carcinoma [10]. The further data suggested that
RhoGDI may promote tumor progression by stimulating tumor cell
growth and migration [11]. Similarly, a comparative proteomic
analysis revealed that RhoGDI was upregulated in oral squamous
cell carcinoma and validated as an independent prognostic indictor
for overall survival [26]. Recently, a proteomics-based study
searched and identiﬁed RhoGDI as a metastasis-related protein in
colon and prostate cancer [24]. In other research about prostate
cancer, however, RhoGDI was identiﬁed as a tumor suppressor
and inhibited the growth in vitro and tumorigenic ability of pros-
tate tumor xenografts in vivo [25]. To sum up, the role of RhoGDI
in cancer progression remains controversial. Recently, Ding et al.
showed that RhoGDI functions as a metastasis suppressor and
can block miR-151-induced HCC cell migration and invasion, sug-
gesting its role in HCC progression [12]. Unfortunately, the re-
search was involved in a small-samples analysis with incomplete
clinicopathological parameters. To address this question, we ana-
lyzed RhoGDI protein expression in 147 clinicopathologically char-
acterized HCC cases by immunohistochemistry. The statistical
evaluation showed RhoGDI overexpression was closely associated
with distant relapse of patients with HCC, suggesting its potential
role in HCCmetastasis. Further, our unvariate and multivariate sur-
vival analysis still cannot support RhoGDI overexpression as an
independent predictor of HCC patients.
Until now, no functional evidence of RhoGDI has been docu-
mented. Our previous data suggested that RhoGDI may promote
CRC progression by stimulating tumor cell growth and migration
[11]. A recent research revealed that miR-151 is a crucial stimulus
for HCC invasion and metastasis by directly targeting RhoGDI [12].
In the present study, RhoGDI overexpression promoted cell prolif-
eration and migration in vitro. RhoGDI knockdown inhibited
aggressive phenotype of HCC cells, suggesting its role in tumorway. Western blot analysis was used to detect expression of Rho and Rac, the
ted with RhoGDI cDNA. Middle panel, HepG2 cells transfected with RhoGDI siRNA 1
(⁄) indicates P < .05. The representative results were shown from three independent
508 H. Wang et al. / FEBS Letters 588 (2014) 503–508progression. To combine in vitro study with the result of immuno-
histochemistry, we proposed RhoGDI overexpression as a novel
biomarker to predict postoperative distant metastasis of patients
with HCC.
Despite its critical cellular function little is known about molec-
ular mechanism of RhoGDI in HCC progression. As key regulators of
Rho family GTPases, here, we showed RhoGDI signiﬁcantly upreg-
ulated Rho, but not Rac/Cdc42, which are the members of Rho fam-
ily small GTPases. A large number of researches have demonstrated
that Rho family GTPases play important roles in a variety of cellular
functions, such as cell migration and reorganization of the ﬁlamen-
tous actin system [18,19]. Further studies revealed that PI3K/AKT
and MAPK signal transduction cascades were activated by RhoGDI
because of increased phosphorylation of ERK and AKT. This helps to
provide evidence for diverse molecular mechanism by which Rho-
GDI promote cell growth and proliferation.
5. Conclusion
Our study evaluated clinical signiﬁcance of RhoGDI and its pre-
dictive value for distant metastasis in a large number of HCC clin-
ical tissue specimens at protein level by immunohistochemical
analysis. Further in vitro study was performed to achieve a better
understanding of its functions in HCC progression. The most valu-
able ﬁnding of this study is that distant metastasis of our study co-
hort was signiﬁcantly more frequently in high RhoGDI expression
cases that in low RhoGDI expression cases. It indicates that RhoGDI
overexpression is a new predictor for postoperative distant metas-
tasis of HCC patients. Therefore, its clinical value lies in that closer
monitoring and more aggressive treatment should be indicated for
the HCC patients with RhoGDI overexpression. This may be a useful
way to reduce mortality and prolong the survival time as much as
possible. Modulation of the tumor aggressive effect through inhib-
iting PI3K/AKT or MAPK activation mediated by RhoGDI overex-
pression might be used as a potential target for HCC prevention
and therapy.
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